Theranostics 2016; 6(2):243-253. doi:10.7150/thno.14322 This issue Cite

Research Paper

Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding

Haojun Chen1, 2, Guohao Wang3, Lixin Lang2, Orit Jacobson2, Dale O. Kiesewetter2, Yi Liu2, Ying Ma2, Xianzhong Zhang2✉, Hua Wu1✉, Lei Zhu3✉, Gang Niu2✉, Xiaoyuan Chen2✉

1. Department of Nuclear Medicine, Xiamen Cancer Center, the First Affiliated Hospital of Xiamen University, Xiamen, China
2. Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA
3. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361005, China

Citation:
Chen H, Wang G, Lang L, Jacobson O, Kiesewetter DO, Liu Y, Ma Y, Zhang X, Wu H, Zhu L, Niu G, Chen X. Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. Theranostics 2016; 6(2):243-253. doi:10.7150/thno.14322. https://www.thno.org/v06p0243.htm
Other styles

File import instruction

Abstract

Graphic abstract

The efficacy of therapeutic drugs is highly dependent on their optimal in vivo pharmacokinetics. Albumin conjugation is considered to be one of the most effective means of protracting the short lifespan of peptides and proteins. In this study, we proposed a novel platform for developing long lasting therapeutics by conjugating a small molecular albumin binding moiety, truncated Evans blue, to either peptides or proteins. Using the anti-diabetic peptide drug Exendin-4 as a model peptide, we synthesized a new long-acting Exendin-4 derivative (denoted as Abextide). Through complexation with albumin in situ, the biological half-life of Abextide was significantly extended. The hypoglycemic effect of Abextide was also improved remarkably over Exendin-4. Thus, Abextide has considerable potential to treat type 2 diabetes. This strategy as a general technology platform can be applied to other small molecules and biologics for the development of long-acting therapeutic drugs.

Keywords: Exendin-4, Evans blue, Albumin-binding, PET, Abextide


Citation styles

APA
Chen, H., Wang, G., Lang, L., Jacobson, O., Kiesewetter, D.O., Liu, Y., Ma, Y., Zhang, X., Wu, H., Zhu, L., Niu, G., Chen, X. (2016). Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. Theranostics, 6(2), 243-253. https://doi.org/10.7150/thno.14322.

ACS
Chen, H.; Wang, G.; Lang, L.; Jacobson, O.; Kiesewetter, D.O.; Liu, Y.; Ma, Y.; Zhang, X.; Wu, H.; Zhu, L.; Niu, G.; Chen, X. Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. Theranostics 2016, 6 (2), 243-253. DOI: 10.7150/thno.14322.

NLM
Chen H, Wang G, Lang L, Jacobson O, Kiesewetter DO, Liu Y, Ma Y, Zhang X, Wu H, Zhu L, Niu G, Chen X. Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. Theranostics 2016; 6(2):243-253. doi:10.7150/thno.14322. https://www.thno.org/v06p0243.htm

CSE
Chen H, Wang G, Lang L, Jacobson O, Kiesewetter DO, Liu Y, Ma Y, Zhang X, Wu H, Zhu L, Niu G, Chen X. 2016. Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. Theranostics. 6(2):243-253.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image